NEW YORK (GenomeWeb News) – Quest Diagnostics has struck multi-year agreements with both Illumina and Life Technologies to use their respective sequencing technologies for clinical testing, the firms said today.

Under two separate agreements, Quest will have the right to develop and offer molecular laboratory-developed tests using Illumina's MiSeq and Life Tech's Ion Torrent platforms and the respective related reagents for clinicians and clinical trials performed by its pharmaceutical and biotechnology clients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.

The New York Times editorial board weighs in on scientific research misconduct.

The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.